A nice demonstration again in a placebo controlled trial that recombinant EPO is safe and effective in anemic cancer patients on chemorx. The three times weekly dose is more commonly […]
An exciting issue is studied in this head/neck cancer patient population. Perioperative EPO may have a role to decrease blood transfusion needs and speed recovery. While this is only a […]
Important to attempt review, but too much variability in studies to form meaningful conclusion. – Patricia Ford
In this prospective randomized study, intraoperative acute isovolemic hemodilution (ANH) was not associated with a reduction in the need for allogeneic blood transfusion. However, this study evaluated the contribution of […]
This study supports the hypothesis that aprotinin is an anticoagulant which prolongs the aPTT and has no or marginal risks of thromboembolic complications. – Wulf Dietrich.
An excellent study about the use of AT III in septic patients. Carefully conducted study: the description in the method section is outstanding. It is noteworthy that this is the […]
NATA: Network for the advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and ther heathcare professionals.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.